Compare BioNano Genomics Inc (BNGO) vs Virgin Galactic Holdings, Inc. (SPCE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Virgin Galactic Holdings, Inc. — how do they compare? BioNano Genomics Inc trades at $1.17 (market cap $13.66M), while Virgin Galactic Holdings, Inc. trades at $3.29 (market cap $498.02M). The key difference: Virgin Galactic Holdings, Inc. is far larger — about 36.5× BioNano Genomics Inc's market cap, and Virgin Galactic Holdings, Inc. is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | SPCE | |
|---|---|---|
Market Cap | $13.66M | $498.02M |
Sector | Health | Industrials |
52-Week High | $4.92 | $7.52 |
52-Week Low | $1.06 | $2.17 |
Enterprise Value | $16.26M | $597.87M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.16 with a bullish technical signal supported by moving averages. The company shows improving financial trends with narrowing losses and consistent earnings beats, though it remains unprofitable with negative margins. Recent news highlights operational progress including debt retirement and scientific publications. Valuation ratios appear attractive with P/S of 0.31 and P/B of 0.36.
The outlook remains speculative given persistent losses, but improving cash flow trends and analyst optimism provide catalysts. Key risks include ongoing negative profitability and competitive pressures in genomics. With 57% analyst buy ratings and bullish technical momentum, the stock offers high-risk growth potential for investors comfortable with biotech volatility.
Virgin Galactic (SPCE) trades at $3.23, up 4.19% on the day, with a bullish technical signal from moving averages but overbought RSI levels near 91.63. The company continues to report significant losses, with a net income margin of -19,781.3% in 2025 and negative cash flow from operations of $240.14 million. Recent news highlights focus on upcoming Q2 2026 earnings and sector volatility amid SpaceX's market debut.
The outlook remains high-risk due to persistent unprofitability and cash burn, though recent quarterly EPS beats offer some optimism. Investment opportunity hinges on successful commercialization of space tourism, while risks include intense competition, funding needs, and execution challenges. Analyst sentiment is mixed with 29.41% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Virgin Galactic Holdings, Inc.
Virgin Galactic Holdings Inc. develops space vehicles. The Company designs exploration technology such as missiles, rockets, and other related equipment. Virgin Galactic Holdings serves customers in the United States.
Read more on SPCE →
